American Society of Hirudotherapy

Taxonomy & Species Identification

Molecular systematics, morphological identification, and regulatory implications of the Hirudo medicinalis species complex

Last Updated: May 26, 2026Reviewed by: Andrei Dokukin, MD
Descriptive biologyEducational reference

Taxonomy context: The salivary secretions of all three species (H. medicinalis, H. verbana, H. orientalis) have been profiled by mass spectrometry (Babenko et al. 2020). See the Coverage Map for what is and isn't studied per condition, and the Research Roadmap for ASH's gap priorities.

This page presents the taxonomic classification and species identification of medicinal leeches based on peer-reviewed systematics, molecular phylogenetics, and comparative genomics. Species-level identification has direct implications for FDA regulatory compliance: the first 510(k) clearance (K040187) references “Hirudo medicinalis” (later clearances K132958 and K140907 name H. verbana), and molecular evidence demonstrates that commercially supplied leeches are predominantly H. verbana. Data are sourced from taxonomy, molecular biology, and regulatory literature spanning 1758–2024.

FDA-Cleared Indication

Medicinal leeches are freshwater annelids belonging to the genus Hirudo Linnaeus, 1758. Leeches as a group are distributed across every continent except Antarctica. Of approximately 680 described leech species, most live in freshwater; the group includes both predatory and blood-feeding species. Among the blood-feeders, three closely related species — H. medicinalis, H. verbana, and H. orientalis — constitute the “medicinal leech species complex” used in clinical hirudotherapy and cleared by the FDA as 510(k) medical devices. The taxonomy of this complex has undergone a fundamental revision since 2005: what was long considered a single polymorphic species with three subspecies has been demonstrated, through mitochondrial and nuclear DNA analysis, to comprise three distinct species with allopatric distributions, subtle morphological differences, and potentially divergent pharmacological profiles. This species problem has profound implications for regulatory documentation, clinical standardization, and pharmacological research.

This page provides a complete treatment of medicinal leech taxonomy: the formal hierarchical classification with historical authorities, the landmark molecular revision by Siddall et al. (2007), comparative salivary transcriptomics by Babenko et al. (2020), FDA-cleared suppliers and their 510(k) clearances, morphological identification keys, dangerous look-alike species, color variation documented by Moquin-Tandon (1846), global hematophagous leech diversity, molecular identification methods (COI barcoding), and the clinical significance of accurate species identification for regulatory compliance and pharmacological reproducibility.

Formal Taxonomic Classification

The genus Hirudo was first designated by Carl Linnaeus in the 10th edition of Systema Naturae (1758), with H. medicinalis as the type species. Formal classification was refined through 19th-century monographs by Moquin-Tandon (1827, 1846), Grube (1844), Leuckart (1863), and Metschnikoff (1871), with the modern family-level framework established by Whitman (1878, 1886, 1887). Subsequent contributions from Bergh (1885), Apathy (1888), Cuenot (1891), Livanov (1940), Lukin (1976), and the encyclopedic treatment by Sawyer (1986) completed the pre-molecular taxonomy of the Hirudinidae.

RankTaxonAuthorityNotes
PhylumAnnelidaLamarck, 1809Segmented worms; ~21,000 species. Leeches are a derived lineage nested within Clitellata (the group that includes the former 'oligochaetes')
ClassHirudineaLamarck, 1818All leeches; ~680 species worldwide. Fixed segment count (32 true somites), anterior and posterior suckers, hermaphroditic reproduction
SubclassEuhirudineaLukin, 1956True leeches: all leeches except the bristle-bearing genus <em>Acanthobdella</em> (order Acanthobdellida, Livanow 1905)
OrderArhynchobdellidaBlanchard, 1894Jawed leeches with three muscular jaws arranged in a triradiate pattern (the “Mercedes-Benz sign” bite mark); ~100 teeth per jaw
FamilyHirudinidaeWhitman, 1878Obligate sanguivorous (blood-feeding) leeches with highly developed salivary glands; includes all “true” medicinal leeches. Founded by C.O. Whitman in his landmark monograph
SubfamilyHirudininaeBlanchard, 1892Old World medicinal leeches with paired dorsal longitudinal stripes; distinguished from New World Macrobdellinae by jaw dentition and pigmentation
GenusHirudo L.Linnaeus, 1758Three recognized medicinal species plus several non-medicinal congeners. Distributed across the Palearctic from Scandinavia to Central Asia
Type speciesHirudo medicinalisLinnaeus, 1758The nominotypical species. Northern European range. CITES Appendix II; European Red List (Near Threatened). Rare in current commercial supply
The hierarchical classification above follows the system used in FDA 510(k) documentation. The first clearance (K040187) names Hirudo medicinalis, while the later clearances (K132958, K140907) name Hirudo verbana, and molecular evidence (Section 2) demonstrates that most commercially supplied leeches belong to H. verbana. Whether this discrepancy has pharmacological significance remains an open research question (Babenko et al., 2020).

Key Taxonomic Authorities — Historical Timeline

YearAuthorContribution
1758LinnaeusSystema Naturae 10th ed. — formal description of genus Hirudo and species H. medicinalis
1820CarenaFirst description of H. verbana from southern European specimens (Lake Verbano/Lago Maggiore region)
1827Moquin-TandonMonographie de la famille des Hirudinées — first thorough leech monograph
1844GrubeExpanded morphological descriptions of European Hirudinea
1846Moquin-TandonDocumented 19 color variations within H. medicinalis; established color pattern taxonomy
1863LeuckartDetailed internal anatomy and reproductive biology of Hirudinea
1871MetschnikoffEmbryological studies; comparative developmental morphology
1878, 1886, 1887WhitmanEstablished Family Hirudinidae; laid foundation for modern leech taxonomy with three landmark publications
1885BerghComparative histology of leech tissues
1888ApathyNeuroanatomy and connective tissue studies in Hirudinea
1891CuenotPhysiological studies of leech blood and excretory systems
1903SukatschoffEmbryonic development of leeches: cleavage and formation of the embryonic rudiments in Nephelis vulgaris (Herpobdella atomaria)
1940LivanovClass Hirudinea chapter in the Soviet Manual of Zoology (Vol. II); cited for leech morphology, ecology and taxonomy
1956LukinIntroduced the subclasses Archihirudinea (Acanthobdella) and Euhirudinea (true leeches, including Hirudo); reorganized higher-level leech classification
1976LukinUpdated Soviet leech monograph integrating ecological and biogeographic data
1986SawyerThree-volume reference work on leech biology. Covers anatomy, physiology, behaviour, feeding biology, ecology and systematics, with a key to the leeches of each zoogeographical region and a bibliography
2004BaskovaRecognized three subspecies: H. m. medicinalis (therapeutic), H. m. officinalis (apothecary), H. m. orientalis (eastern). Later revised by molecular evidence
2005Utevsky & TronteljFormal description of H. orientalis sp. nov. from Turkish/Central Asian specimens
2007Siddall et al.Molecular study (mtDNA COI barcoding + nuclear microsatellites) showed that European medicinal leeches comprise at least three species and that leeches marketed as H. medicinalis are H. verbana. Confirmed earlier work (Nesemann & Neubert 1999; Trontelj & Utevsky 2005)

The Species Problem: H. medicinalis vs H. verbana vs H. orientalis

For over two centuries, the medicinal leech was treated as a single species, Hirudo medicinalis Linnaeus, 1758, with geographic variation expressed as subspecies or color morphs. The Russian tradition (Baskova, 2004) recognized three subspecies: H. medicinalis medicinalis (the “therapeutic” form), H. medicinalis officinalis (the “apothecary” form), and H. medicinalis orientalis (the eastern form, which inhabits predominantly the southern republics of the former Soviet Union). This subspecific framework was used in Russian hirudotherapy literature through the early 2000s and remains referenced in the official Russian instructions for use of some registered medicinal-leech products.

Siddall et al. 2007 — The Landmark Molecular Revision

In 2007, Mark Siddall and colleagues at the American Museum of Natural History published a significant study in Proceedings of the Royal Society B that fundamentally altered the taxonomy of medicinal leeches. Using mitochondrial DNA (cytochrome oxidase subunit I, COI) sequencing combined with nuclear microsatellite analysis of wild Hirudo collected in France, Italy, Slovenia, Croatia, Ukraine and Macedonia and of commercially supplied leeches, they showed that there are at least three species of European medicinal leech:

  • Genetic divergence between the three lineages exceeds the threshold recognized for species-level separation in annelids
  • Each lineage forms a reciprocally monophyletic clade on both mitochondrial and nuclear gene trees — the gold standard criterion for species delimitation
  • The three species show distinct, belt-shaped east–west ranges associated with different climatic and vegetation zones (Utevsky et al., 2010)
  • Morphological differences, while subtle, are consistent with the molecular groups — particularly in dorsal coloration, ventral pigmentation, and jaw dentition patterns
Critical regulatory implication: The majority of leeches supplied commercially under the label “Hirudo medicinalis” — including those from the largest FDA-cleared supplier, Ricarimpex SAS — are actually H. verbana. This means that published studies that used commercially supplied leeches labelled “H. medicinalis” very likely used H. verbana, so their outcomes may reflect that species. Whether pharmacological differences between species are clinically significant remains an open investigation question.

The Three Medicinal Species — Detailed Profiles

Hirudo medicinalis Linnaeus, 1758

Common name: Northern medicinal leech

  • Range: Restricted to northern Europe — Scandinavia, northern Germany, Baltic states, northern Russia. The most geographically restricted of the three species
  • Conservation status: CITES Appendix II (international trade regulated); European Red List (Near Threatened). Wild populations have declined dramatically since the 19th-century “leech mania” when billions were harvested
  • Commercial availability: Rare in current commercial supply. Most suppliers have shifted to the more easily bred H. verbana
  • Morphology: Olive-green dorsum with prominent orange-yellow longitudinal stripes; typically darker overall coloration than H. verbana; ventral surface often uniformly olive-green without significant spotting
  • Nomenclatural note: As the type species, H. medicinalis is the name referenced in the first FDA 510(k) clearance (K040187); the Biopharm clearance (K132958) names H. verbana, and the Carolina clearance (K140907) names H. verbana, alternatively H. medicinalis

Hirudo verbana Carena, 1820

Common name: Southern (Hungarian) medicinal leech

  • Range: Southern and southeastern Europe — Mediterranean basin, Balkans, Hungary, Romania, Ukraine (south), Turkey (European part). Named after Lake Verbano (Lago Maggiore) in the Italian-Swiss border region
  • Commercial dominance: The most commonly supplied species worldwide. Ricarimpex SAS (Eysines, France) and Biopharm (Swansea, Wales) both primarily breed H. verbana. Virtually all clinical studies published since the 1990s used this species
  • Clinical significance: When a published study reports outcomes with “H. medicinalis,” the actual species is almost certainly H. verbana unless the study explicitly performed molecular verification
  • Morphology: Brighter green coloration than H. medicinalis; prominent orange-yellow dorsal stripes; ventral surface characteristically pale with variable dark spots or blotches; generally considered the most colorful of the three species
  • Breeding advantage: Adapts more readily to captive breeding conditions, with higher fecundity and faster growth rates than H. medicinalis

Hirudo orientalis Utevsky & Trontelj, 2005

Common name: Eastern (Oriental) medicinal leech

  • Range: Turkey, Iran, Azerbaijan, Uzbekistan, and adjacent Central Asian regions. Extends eastward to the limits of the genus Hirudo distribution
  • Clinical use: Widely used in CIS countries (Russia, Ukraine, Kazakhstan, Uzbekistan) for hirudotherapy. This is the species most Russian clinical literature (including Baskova’s work) likely refers to when discussing the “oriental subspecies”
  • Taxonomic history: Formally described as a new species by Utevsky & Trontelj (2005) based on morphological and molecular evidence. Previously classified as H. medicinalis orientalis
  • Morphology: Variable coloration; dorsal stripes present but may be less pronounced than in H. medicinalis or H. verbana; ventral surface typically dark or greenish with variable spotting
  • FDA status: Not specifically cleared by FDA. No US-market supplier is known to specifically source H. orientalis, though it may be present in unverified supply chains

Babenko et al. 2020 — Comparative Salivary Transcriptomics

Building on the species framework established by Siddall et al. (2007), Babenko and colleagues (2020) assembled and annotated a draft genome of H. medicinalis and compared salivary-cell transcriptomes (RNA-seq of salivary cells) of the three medicinal leech species, H. medicinalis, H. verbana, and H. orientalis, with proteomic validation of the salivary cell secretions of each species.

Key Findings

  • Broadly conserved salivary repertoire: All three species express the core set of bioactive molecules essential for blood feeding — M12 and M13 metalloprotease families, CRISP (cysteine-rich secretory) proteins, apyrase, adenosine deaminase, cystatins, hyaluronidase, and ficolins
  • Differential expression patterns: Despite the conserved repertoire, quantitative expression levels of specific gene families differ between species. This raises the possibility that salivary pharmacological potency may vary between species, even if the qualitative composition is similar
  • Draft genome sequences: Assembly statistics provided for all three species, enabling future studies to identify species-specific regulatory elements, gene duplications, and pseudogenes
  • M12/M13 metalloprotease expansion: Both protease families show evidence of lineage-specific duplications, suggesting that extracellular matrix degradation — a key function during blood feeding — may be under positive selection
  • Conservation of core anticoagulant machinery: Hirudin, destabilase, and the major thrombin/factor Xa inhibitors are present in all three species at both transcript and predicted protein levels
Clinical interpretation: The Babenko et al. (2020) findings suggest that the three medicinal leech species have broadly equivalent pharmacological potential for the FDA-cleared indications (venous congestion relief). However, the differential expression patterns leave open the possibility that species choice could matter for specific non-cleared research applications targeting particular bioactive molecules. This remains an active investigation question with no definitive clinical answer.

Molecular Identification Methods

Morphological identification of Hirudo species is unreliable due to extensive intraspecific color variation and subtle interspecific differences. Molecular methods provide the only definitive species identification. The standard approach uses DNA barcoding with the mitochondrial cytochrome oxidase subunit I (COI) gene.

COI Barcoding Protocol

ParameterStandard Approach
Target geneCytochrome oxidase subunit I (COI / cox1)
Fragment length~658 bp (Folmer region) — the universal DNA barcode fragment
PrimersLCO1490 / HCO2198 (Folmer et al., 1994) — universal invertebrate COI primers
Sample sourcePosterior sucker tissue clip (non-lethal) or whole-body DNA extraction
Reference databaseBOLD (Barcode of Life Database) and GenBank; reference sequences deposited by Siddall et al. (2007) and subsequent studies
Interspecific divergenceTypically 5–10% between H. medicinalis, H. verbana, and H. orientalis — well above the 2–3% barcoding gap threshold
Turnaround time2–5 working days from tissue sample to species ID (standard Sanger sequencing)
Supplementary markersNuclear ITS (internal transcribed spacer) for confirmation in ambiguous cases; multilocus approaches recommended for phylogeographic studies

DNA barcoding is now the gold standard for medicinal leech species verification. The method is straightforward, inexpensive ($30–50 per sample at commercial sequencing facilities), and definitive. For clinical and regulatory purposes, COI barcoding provides unambiguous identification where morphology cannot.

No current FDA 510(k) clearance requires molecular species verification as a condition of supply. However, as awareness of the species problem grows, institutional quality assurance programs may begin incorporating periodic COI barcoding of incoming leech shipments — particularly in academic medical centers conducting research alongside clinical use.

FDA-Cleared Suppliers & Regulatory Framework

Medicinal leeches are classified by the FDA as FDA 510(k)-cleared medical devices under product code NRN. They require 510(k) premarket notification (not PMA approval) and are cleared for prescriptive, single-use application. As of 2024, three suppliers hold active 510(k) clearances.

FDA 510(k)-Cleared Medicinal Leech Suppliers
StudyDesignPopulation (n=)InterventionKey OutcomeResult
Ricarimpex SAS
2004
FDA 510(k) clearanceMedicinal leeches (Hirudo sp.) bred at Eysines facility, France
(n=NR)
510(k) K040187 — First FDA clearance of medicinal leeches as FDA-cleared medical deviceTwo cleared indications: (1) adjunct to healing of graft tissue with venous congestion, (2) creating prolonged localized bleeding to relieve venous congestionCleared 2004. Ricarimpex is the primary global supplier; most clinical studies in the literature sourced leeches from this facility
Prescriptive use, single-use only. Species listed as H. medicinalis but per Siddall et al. 2007, likely H. verbana
Biopharm (UK) Ltd.
2014
FDA 510(k) clearanceMedicinal leeches bred at Hendy facility, Swansea, Wales, UK
(n=NR)
510(k) K132958 — FDA clearance for medicinal leeches as FDA-cleared medical deviceSame two indications as K040187: venous congestion adjunct and prolonged localized bleedingCleared approximately 2014. Second international supplier with FDA market access; supplies both UK and US hospitals
Biopharm breeds leeches under pharmaceutical-grade conditions; Roy Sawyer (author of 1986 monograph) founded this company
Carolina Biological Supply Co.
2015
FDA 510(k) clearanceMedicinal leeches distributed from Burlington, North Carolina, USA
(n=NR)
510(k) K140907 — FDA clearance for medicinal leeches as FDA-cleared medical deviceSame cleared indications: venous congestion adjunct and prolonged localized bleedingCleared 2015. First US-based supplier with 510(k) clearance; reduces supply chain delays for domestic hospitals
Carolina Biological is primarily known as a science education supplier; their FDA-cleared medical leech line represents a distinct product category

Cleared Indications (All Three 510(k) Clearances)

  1. Venous congestion adjunct: As an adjunct to the healing of graft/flap tissue when problems of venous congestion may delay healing or cause tissue necrosis
  2. Prolonged localized bleeding: For overcoming problems of venous congestion by creating prolonged, localized bleeding at the site of application

Regulatory Classification Details

ParameterValue
Device classPre-amendment (510(k) required)
Product codeNRN
Regulation number878.4910
Clearance pathway510(k) premarket notification
Use restrictionPrescriptive use only (requires physician order)
Reuse policySingle-use only — leeches must be humanely euthanized after application (immersion in 70% or higher alcohol for at least 5 minutes, then disposal as biohazard waste)
Species referencedHirudo medicinalis (note: actual species supplied is predominantly H. verbana)
The discrepancy between the species referenced in 510(k) documentation (H. medicinalis) and the species actually supplied (H. verbana) has been noted in the literature (Siddall et al., 2007). FDA has since cleared medicinal leeches identified as H. verbana under a separate 510(k) (K132958, 19 February 2014), with the original H. medicinalis clearance (K040187) as predicate. The comparative transcriptomic data from Babenko et al. (2020) — showing broadly similar salivary profiles — may provide scientific justification for treating the species as functionally equivalent for the cleared indications. However, formal bioequivalence studies have not been conducted.

Morphological Identification & Diagnostic Features

While molecular methods provide definitive species identification, morphological assessment remains the first-line approach in clinical settings and field work. The following diagnostic features are used to identify medicinal leeches and distinguish them from dangerous look-alike species.

Primary Diagnostic Characters

CharacterDescriptionDiagnostic Value
Dorsal stripesOrange-yellow longitudinal stripes running the length of the dorsum, typically 2–6 prominent stripes with variable accessory markingsMost reliable field identification character. Present in all three Hirudo species; absent in dangerous look-alikes
Base colorationOlive-green ground color with variable shades from dark forest green to bright yellowish-green, depending on species, age, feeding state, and individual variationUseful but highly variable; not reliable for species-level identification alone (see Moquin-Tandon 19 variations)
Ventral surfacePale, dark, or green; may feature dark/black spots. H. verbana typically shows pale ventral with scattered spots; H. medicinalis tends toward uniform olive-greenVentral pattern differences may assist in provisional species assignment but require molecular confirmation
Body sizeLarge: >10 cm (extended); Medium: 3–8 cm.Size varies enormously with age and feeding state; fasting adults average 2–3 g; engorged specimens reach 10–15 g (5× body weight in blood)
Jaw apparatusThree muscular jaws arranged in triradiate (Y-shaped) pattern; each jaw bearing ~80–100 sharp teeth. Produces characteristic “Mercedes-Benz sign” bite markJaw strength and tooth count distinguish Hirudo from jawless leeches and from Limnatis nilotica (weak jaws, 27–45 teeth)
AnnulationEach true somite divided into 5 annuli (rings); total body annuli typically 95–102; head end narrower, posterior broader with large caudal suckerAnnulation count assists in generic identification; consistent within Hirudinidae
Sensory papillaeSegmentally arranged sensory papillae on dorsal surface; 5 pairs of eyes on anterior segments arranged in a dorsal arcEye arrangement pattern aids in family-level identification; consistent across Hirudo

Size and Weight Reference Data

StateLength (cm)Weight (g)Notes
Fasting adult (typical)8–122–3Standard clinical-use size; most suppliers ship leeches in this range
Medium (subadult)3–80.5–1.5Used in delicate applications (ophthalmology, pediatrics)
Engorged (post-feeding)10–1510–15Ingests 5–15 mL blood per feeding; roughly 5–9× body weight (about 4.8× in 2-g and 8.2× in 1-g leeches). Detaches spontaneously after 20–45 minutes
Maximum recorded4438.8Shchegolev & Fedorova; captive-raised specimen under optimized laboratory conditions

Color Variation — The 19 Moquin-Tandon Varieties (1846)

Alfred Moquin-Tandon, in his 1846 monograph on the Hirudinea, documented 19 distinct color variations within what was then classified as Hirudo medicinalis. This remarkable phenotypic diversity, recorded before the concepts of cryptic species or subspecies were well established, reflects three sources of variation: (1) genuine intraspecific polymorphism within each species, (2) interspecific differences between H. medicinalis, H. verbana, and H. orientalis (unknowingly mixed in 19th-century collections), and (3) ontogenetic and condition-dependent changes (age, feeding status, water chemistry).

Moquin-Tandon’s classification remains historically significant and is still cited in modern taxonomic literature as evidence that color alone is insufficient for species-level identification. His varieties encompassed the full spectrum from nearly black specimens to bright green individuals with vivid orange stripes, and included variations in dorsal stripe number, width, and intensity; ventral coloration ranging from pale cream to nearly black; and the presence, absence, and distribution of spots and blotches.

Dorsal Ground Color Spectrum

  • Dark olive-green (most common)
  • Bright olive-green
  • Yellowish-green
  • Brown-green
  • Dark brown approaching black
  • Russet-brown (rare)

Dorsal Stripe Patterns

  • Broad, vivid orange-yellow paired stripes
  • Narrow, faint stripes (barely visible)
  • Interrupted/fragmented stripes
  • Multiple accessory lateral stripes
  • Confluent stripes merging into dorsal band
  • Orange-red stripe variant (rare)

Ventral Surface Patterns

  • Pale cream to yellowish (most common in H. verbana)
  • Uniform olive-green (typical H. medicinalis)
  • Dark greenish-black
  • Scattered dark spots on pale background
  • Dense spotting approaching uniform dark
  • Lateral margin color different from ventral center
Modern interpretation: Some of Moquin-Tandon’s 19 varieties likely represent different species within the Hirudo complex (particularly the distinction between pale-ventral “verbana-type” and dark-ventral “medicinalis-type” specimens), while others reflect genuine within-species polymorphism. Only molecular identification can resolve this ambiguity. The practical lesson for clinicians: the species of a medicinal leech cannot be determined by visual inspection alone.

Dangerous Look-Alike Species — Safety-Critical Identification

Patient safety alert: Two non-medicinal leech species share habitats with Hirudo and may be accidentally collected or misidentified. One of these — Limnatis nilotica (the Nile horse leech) — is a dangerous parasite that causes hemorrhage, hemoptysis, and potentially fatal suffocation. Correct identification is a non-negotiable safety requirement for any practitioner collecting leeches from wild or semi-wild populations.

Limnatis nilotica (Savigny, 1822) — Nile/Egyptian Horse Leech

Limnatis nilotica is the single most dangerous leech species that could be confused with a medicinal leech. Unlike Hirudo, which feeds from the external skin surface, Limnatis nilotica enters body cavities (nose, pharynx, larynx, vagina, urethra, rectum) and attaches to mucosal surfaces. Its small, weak jaws (27–45 teeth per jaw, compared to 80–100 in Hirudo) are adapted for thin mucosal tissue, not skin.

Clinical Hazards

  • Hemorrhage: Persistent mucosal bleeding from attachment site; salivary anticoagulants prevent clotting
  • Hemoptysis: When attached in the pharynx or larynx, causes coughing of blood
  • Airway obstruction: Pharyngeal/laryngeal attachment can cause suffocation — documented fatal cases in the medical literature
  • Anemia: Prolonged undetected attachment causes chronic blood loss anemia

How to Distinguish from Hirudo

CharacterHirudo (medicinal)Limnatis nilotica (dangerous)
Dorsal stripesPRESENT — orange-yellow longitudinal stripes (the single most reliable distinguishing character)ABSENT — no dorsal longitudinal stripes
Lateral stripesOrange-yellow stripes are DORSAL, not lateralOrange lateral stripes PRESENT (lateral, not dorsal — opposite position from Hirudo)
Jaw strengthStrong muscular jaws; 80–100 teeth per jaw; easily penetrates intact skinWeak jaws; 27–45 teeth per jaw; can only penetrate thin mucosal surfaces
Feeding behaviorAttaches to external skin surface; detaches spontaneously after satiationEnters body cavities (nose, pharynx, etc.); attaches to mucosal surfaces internally
Overall colorationOlive-green with stripe pattern; distinct dorsal/ventral color differentiationUniform brownish-olive or brownish-green; less distinct dorsal/ventral differentiation
Geographic rangeEurope, Turkey, Central AsiaNorth Africa (Nile basin), Middle East, southern Europe (Mediterranean)

Haemopis sanguisuga (Linnaeus, 1758) — False Horse Leech

Haemopis sanguisuga, despite its alarming species epithet (“blood-sucker”), is not a blood-feeding species. It is a predator of invertebrates (earthworms, insect larvae, snails) and shares freshwater habitats with Hirudo across much of Europe and western Asia. While not directly dangerous, its misidentification as a medicinal leech would result in therapeutic failure — it produces no anticoagulant secretion and cannot feed from human skin.

Distinguishing Characters

CharacterHirudo (medicinal)Haemopis sanguisuga (false)
Orange stripesPRESENT — prominent dorsal stripesCOMPLETELY ABSENT — no orange coloration of any kind
Dorsal colorOlive-green with distinct stripe patternUniform dark brown to nearly black; no pattern
Ventral colorPale, dark, or green with possible spottingDirty grayish-green; uniform, unpatterned
Feeding modeObligate hematophage (blood feeder); penetrates skin with sharp-toothed jawsPredator/scavenger of invertebrates; does NOT feed on blood; cannot penetrate human skin
Salivary secretionRich anticoagulant secretion (hirudin, destabilase, calin, etc.)No anticoagulant secretion; salivary glands poorly developed
Therapeutic valueFDA-cleared medical deviceNone — misidentification leads to therapeutic failure
Summary identification rule: The single most reliable field character for identifying a medicinal leech is the presence of orange-yellow dorsal longitudinal stripes. If dorsal stripes are absent, the specimen is NOT a medicinal leech — it may be Limnatis nilotica (dangerous) or Haemopis sanguisuga (harmless but useless). If in doubt, do not use the specimen clinically. FDA-cleared leeches from verified suppliers eliminate this identification risk entirely.

Global Hematophagous Leech Diversity

While the genus Hirudo dominates clinical hirudotherapy, several other hematophagous leech species have been used historically or studied for their bioactive molecules. Of approximately 650 freshwater leech species worldwide, several dozen are obligate blood feeders. The following are the most significant non-Hirudo hematophagous species in the medical and pharmacological literature.

SpeciesCommon NameRangeSignificance
Hirudo nipponiaJapanese medicinal leechJapan, Korea, ChinaUsed in traditional East Asian medicine for centuries. Closely related to H. medicinalis; similar salivary composition. Studied for hirudin variants and novel anticoagulant peptides
Haementeria officinalisSouth American medicinal leechCentral and South AmericaProboscis-bearing leech (feeds by inserting a proboscis rather than biting with jaws). Source of haementin, a fibrinogenolytic enzyme. Used in traditional medicine across Latin America
Haementeria ghilianiiAmazon giant leechAmazon basin, South AmericaThe largest known hematophagous leech (up to 45 cm). Source of hementin (distinct from haementin), a potent fibrinolytic enzyme studied for thrombolytic applications. Historically significant in bioactive molecule discovery
Macrobdella decoraNorth American medicinal leechEastern North America (lakes and wetlands)Source of decorsin — a potent glycoprotein IIb/IIIa (GP IIb/IIIa) integrin antagonist with an RGD motif (Seymour et al., 1990). Decorsin has been studied as a potential antiplatelet agent (McLane et al., 1995), and its NMR structure and engineered analogs with higher anti-platelet activity have been characterized (Krezel et al., 1994; Lao et al., 2016). Distinctively orange-spotted ventral surface
Hirudinaria manillensisAsian buffalo leech / Indian medicinal leechSouth and Southeast Asia (India, Philippines, Indonesia)Used in Ayurvedic and traditional Asian medicine. Source of tandem-hirudin (Lukas et al., 2022) — a tandem two-domain hirudin superfamily member with two globular domains but no thrombin inhibition. Large species used clinically in India
Hirudo troctinaNorth African medicinal leechMorocco, Algeria, Tunisia, Iberian PeninsulaUsed in traditional North African medicine. Closely related to the Hirudo medicinalis complex; molecular phylogenetics places it as a sister taxon. May represent an additional undescribed species-level lineage
Whitmania pigraChinese medicinal leechChina, Southeast AsiaOne of the three leech species listed in the Chinese Pharmacopoeia. Dried leech powder (水蛭, shuizhi) is a standard Traditional Chinese Medicine ingredient. Active pharmacological research on anticoagulant and anti-inflammatory peptides

The pharmacological diversity of hematophagous leeches extends far beyond Hirudo. Each lineage has evolved species-specific bioactive molecules adapted to their particular vertebrate hosts and feeding strategies. This diversity represents an under-explored pharmacological resource: more than 700 leech species have been described, yet only a few are used medicinally and molecular data on salivary secretions come from a small subset of them.

Only Hirudo species are FDA-cleared for clinical use in the United States. The other hematophagous species listed above are of pharmacological and scientific interest, but none holds FDA 510(k) clearance. Their inclusion here is for educational completeness and to illustrate the broader context of leech diversity in which the medicinal leech species complex sits.

Clinical Significance of Species Identification for Regulatory Compliance

The species problem in medicinal leech taxonomy is not merely an academic curiosity — it has direct implications for regulatory compliance, clinical documentation, research reproducibility, and potential pharmacological variability.

Regulatory Implications

510(k) Documentation

Only the first 510(k) clearance (K040187, Ricarimpex, 2004) names “Hirudo medicinalis”; the Biopharm clearance (K132958) names Hirudo verbana and the Carolina clearance (K140907) names H. verbana, with H. medicinalis as an alternative. The actual species supplied is predominantly H. verbana. This nomenclatural discrepancy is recognized in the scientific literature but no FDA recall or enforcement record about it appears in the openFDA device recall and enforcement databases for the leech product code or the three clearance holders.

Risk level: Low for clinical use (salivary profiles are broadly similar per Babenko et al. 2020), but potentially significant for future species-specific regulatory requirements.

Research Reproducibility

Published studies that do not specify which species was actually used (or that use the generic label “H. medicinalis” without molecular verification) may have reduced reproducibility.

Best practice: Research publications should either verify species by COI barcoding or specify the supplier (which allows species inference — e.g., Ricarimpex supplies H. verbana).

Pharmacological Variability

Whether species-level differences in salivary composition translate to clinically meaningful pharmacological differences is the central open question. Babenko et al. (2020) found that the salivary secretions of the three species have a similar composition (39 orthologous protein clusters shared by all three), although the numbers of proteins identified differed (189, 86 and 344).

Unresolved: No head-to-head clinical trial comparing H. medicinalis vs H. verbana vs H. orientalis has been conducted. Such a study would be expensive and logistically challenging given the rarity of H. medicinalis in commercial supply.

Institutional Quality Assurance Recommendations

  1. Source verification: Procure leeches only from FDA-cleared suppliers (Ricarimpex, Biopharm, Carolina Biological) to ensure consistent species and quality
  2. Supply chain documentation: Maintain records of supplier, batch number, and date of receipt for each leech shipment as part of the device traceability record
  3. Periodic molecular verification: Academic medical centers conducting leech therapy research should consider periodic COI barcoding of incoming batches (recommended: annually or with each new supplier contract)
  4. Publication standards: Clinical publications should specify the supplier name and, ideally, the verified species identity; use of the generic term “H. medicinalis” should note the species ambiguity
  5. CITES compliance: Institutions importing leeches from international suppliers must ensure compliance with CITES Appendix II trade documentation requirements for H. medicinalis

Conservation Status & Trade Regulation

The conservation status of medicinal leeches is a direct consequence of historical over-harvesting. During the 19th-century “leech mania” in European medicine, billions of leeches were collected from wild populations. France alone imported an estimated 41.5 million leeches in a single year (1833). This unsustainable harvest devastated wild populations, particularly of the northern H. medicinalis.

RegulationStatusPractical Effect
CITES Appendix IIH. medicinalis listedInternational trade requires export permits from country of origin; import documentation required. Captive-bred specimens from registered facilities (e.g., Ricarimpex) are exempt from some restrictions under CITES Resolution Conf. 10.16
European Red ListNear Threatened (H. medicinalis)Wild collection restricted or prohibited in many European countries. Germany, Switzerland, and Austria have specific protection statutes
EU Habitats DirectiveAnnex VMember states must ensure that exploitation of H. medicinalis is compatible with maintaining favorable conservation status
Bern ConventionAppendix IIIProtected fauna; regulated exploitation under national legislation

Modern clinical supply relies entirely on captive-bred leeches from FDA-cleared facilities. Ricarimpex SAS (France) breeds leeches in the laboratory at Eysines and rears them in basins at Audenge; in 2009 it sold on average about 130,000 specimens per year. Biopharm’s Welsh facility similarly breeds leeches under controlled conditions. This closed-cycle aquaculture model eliminates pressure on wild populations while ensuring consistent supply quality.

CITES Status Confirmed: Both H. medicinalis (CITES term 5353) and H. verbana (CITES term 5354) are explicitly listed in CITES Appendix II. H. orientalis is also covered under the broader Hirudo medicinalis complex listing. International trade in all these species requires appropriate CITES export permits.

Evidence Summary — Taxonomy & Molecular Systematics

The following table summarizes key studies in the taxonomy, molecular systematics, and species identification of medicinal leeches — from the founding monographs of the 18th and 19th centuries through the molecular revolution of the 21st century.

Key Studies in Medicinal Leech Taxonomy & Species Identification
StudyDesignPopulation (n=)InterventionKey OutcomeResult
Siddall ME et al.
2007
Molecular phylogenetic studyHirudo specimens from European, Middle Eastern, and Central Asian populations
(n=NR)
mtDNA COI sequencing + nuclear marker analysis across Hirudo populations previously classified as H. medicinalis subspeciesSpecies-level delimitation within the Hirudo medicinalis complexThree distinct species confirmed: H. medicinalis, H. verbana, and H. orientalis. Genetic divergence exceeds subspecies threshold; reciprocal monophyly demonstrated on gene trees
Landmark study that overturned the 3-subspecies model. Most commercial leeches labeled H. medicinalis are actually H. verbana
Babenko VV et al.
2020
Comparative transcriptomics (RNA-seq)Salivary gland cells from H. medicinalis, H. verbana, and H. orientalis
(n=NR)
RNA-seq of salivary gland tissue across all three medicinal leech species with draft genome assemblyCross-species comparison of salivary transcriptome and bioactive molecule repertoireBroadly similar salivary composition across 3 species: M12/M13 proteases, CRISP proteins, apyrase, adenosine deaminase, cystatins, hyaluronidase, ficolins all conserved. Differential expression patterns exist between species
Draft genome sequences provided for all 3 species. First genome-level comparison of the medicinalis complex
Utevsky SY & Trontelj P
2005
Morphological and molecular taxonomyHirudo specimens from Turkey, Iran, Azerbaijan, and Central Asian regions
(n=NR)
Integrative taxonomy combining morphological characters with molecular phylogenetic analysisFormal description of a new species within the Hirudo medicinalis complexH. orientalis sp. nov. formally described; distinguished by molecular divergence and subtle morphological differences from H. medicinalis and H. verbana
Established the eastern species as taxonomically distinct. Widely used in CIS countries for hirudotherapy
Trontelj P & Utevsky SY
2012
Phylogeographic analysisHirudo medicinalis sensu lato populations across the Palearctic range
(n=NR)
Multilocus phylogeography using mitochondrial and nuclear markers to resolve species boundaries and historical biogeographyRange delimitation and evolutionary history of the three medicinal leech speciesConfirmed allopatric speciation pattern: H. medicinalis concentrated in central, western, and northern Europe; H. verbana dominant in southern/southeastern Europe; H. orientalis across Turkey, Iran, and Central Asia. Contact zones identified in Balkans and Caucasus
Refined the biogeographic ranges first suggested by Siddall et al. 2007
Kvist S et al.
2020
Genome assembly + bioinformatic analysisH. medicinalis reference specimen for whole-genome sequencing
(n=NR)
Draft genome assembly with comprehensive gene annotationGenomic architecture and identification of anticoagulant/antihemostatic gene familiesMultiple anticoagulant and antihemostatic gene families annotated at genome level; a draft reference genome for the genus Hirudo
Provides genomic foundation for resolving interspecific differences at sequence level
Whitman CO
1886
Systematic monographFamily Hirudinidae specimens from global collections
(n=NR)
Full morphological taxonomy establishing family-level classification of medicinal leechesFormal establishment of Family Hirudinidae and subfamily frameworkFamily Hirudinidae formally erected; established morphological characters for genus-level and species-level identification still referenced in modern keys
Foundational work expanded by Whitman 1886, 1887. Sawyer (1986) built directly on this framework
Sawyer RT
1986
Full taxonomic monographGlobal Hirudinea diversity — all known leech species at time of publication
(n=NR)
Encyclopedic synthesis of leech taxonomy, morphology, ecology, and biogeographyDefinitive taxonomic reference for Hirudinea classification and identificationThree-volume work (anatomy, physiology, behaviour, feeding biology, ecology, systematics, bibliography) with a key to the leeches of each zoogeographical region
Three-volume reference work (Clarendon Press, Oxford, 1986); predates the molecular era
Moquin-Tandon A
1846
Morphological surveyH. medicinalis specimens across European populations, focusing on dorsal and ventral coloration
(n=NR)
Systematic documentation of color pattern variation in medicinal leech populationsEnumeration and classification of intraspecific color morphs19 distinct color variations documented within H. medicinalis; established that color alone is insufficient for species-level identification, but dorsal stripe pattern is the most reliable field character
Historical reference still cited for phenotypic variability. Predated understanding that some variation reflected cryptic species
Moquin-Tandon A
1827
Systematic natural history monographHirudinea specimens from French and Mediterranean collections
(n=NR)
First comprehensive treatment of leech systematics as a standalone zoological groupFoundation of leech taxonomy as a scientific disciplineEstablished diagnostic morphological characters (jaw dentition, annulation, color patterns, sucker morphology) that remain in use; formal descriptions of multiple species and varieties
Monographie de la famille des Hirudinées. Preceded Darwin; one of earliest rigorous invertebrate monographs

Evidence Gaps & Research Priorities

Despite the landmark molecular revision of medicinal leech taxonomy and the growing body of comparative genomic data, several important questions remain unresolved. The following gaps represent priorities for future research.

Pharmacological Species Comparison

  • No head-to-head clinical trial comparing H. medicinalis vs H. verbana vs H. orientalis for any indication
  • Whether differences between species in the identified salivary proteins (Babenko et al., 2020) translate to clinically meaningful differences in anticoagulant potency, bleeding duration, or patient outcomes is unknown
  • Standardized in vitro bioassays comparing SGS potency across species have not been published

Genomic & Proteomic Characterization

  • Current draft genomes (Kvist et al., 2020; Babenko et al., 2020) are fragmented; chromosome-level assemblies are needed for all three species
  • Proteomic quantification of salivary composition under standardized conditions across species is incomplete
  • Gene family evolution (duplication, pseudogenization) in anticoagulant gene clusters remains uncharacterized
  • Population genomics of captive-bred vs wild populations (genetic diversity, inbreeding, selection) is unstudied

Regulatory & Quality Assurance

  • FDA 510(k) clearances name different species (H. medicinalis in K040187; H. verbana in K132958 and K140907)
  • CITES applicability to H. verbana and H. orientalis (vs H. medicinalis s.s.) is ambiguous in many jurisdictions
  • No validated quality control assay panel exists for species verification in incoming clinical shipments
  • Retrospective molecular verification of species in landmark clinical studies (which species was actually used?) would strengthen the evidence base

Biogeography & Conservation

  • Contact zone dynamics between H. medicinalis, H. verbana, and H. orientalis in the Balkans and Caucasus are poorly characterized
  • Hybridization potential at range boundaries is unstudied — do hybrids occur in the wild, and if so, what are their pharmacological properties?
  • Wild population census data for all three species are outdated; current Red List assessments may not reflect actual conservation status
  • H. troctina (North Africa) may represent a fourth species in the complex — molecular sampling is insufficient to resolve

Undescribed Diversity

  • Of ~650 freshwater leech species, fewer than 20 have been molecularly characterized for bioactive molecules
  • Tropical hematophagous leeches (Southeast Asia, Africa, South America) likely harbor novel pharmacological compounds adapted to different vertebrate hemostatic systems
  • The tandem-hirudin discovery from Hirudinaria manillensis (Lukas et al., 2022) demonstrates that novel structural variants await discovery even in well-known species
  • Environmental DNA (eDNA) surveys could reveal undescribed hematophagous species in under-sampled regions

Related Research

Genomics & Proteomics2004

Celebrity with a neglected taxonomy: molecular systematics of the medicinal leech (genus Hirudo)

Phylogenetic analysis of nuclear (ITS2+5.8S rRNA) and mitochondrial (12S rRNA, COI) sequences suggests the genus Hirudo is monophyletic, comprising H. medicinalis, East Asian H. nipponia, and three neglected species: H. verbana, H. troctina, and Hirudo sp. n. (variety orientalis).

Trontelj P, Utevsky SY · Molecular phylogenetics and evolution

Genomics & Proteomics2022

Phylogenetic relationships and species delimitation in Haemopis (Annelida: Hirudinea: Haemopidae)

Using COI, 12S, 18S and 28S sequences with morphology, the authors provide a phylogeny and DNA barcodes for the macrophagous leech genus Haemopis, finding a strong but not absolute barcoding gap owing to variation within H. marmorata.

Kvist S et al. · Molecular phylogenetics and evolution

Genomics & Proteomics2021

DNA barcoding for species delimitation of the freshwater leech genus Glossiphonia from the Western Balkan (Hirudinea, Glossiphoniidae)

29 new COI barcodes of Western Balkan Glossiphonia leeches revealed an interspecific threshold of 4-8% K2P distance for species delimitation, and showed that G. nebulosa and G. concolor each comprise more than one phylogenetic clade.

Jovanović M et al. · Biodiversity Data Journal

Genomics & Proteomics2017

Genetic assessment of leech species from yak (Bos grunniens) in the tract of Northeast India

Using COI, 18S, and 28S rDNA markers, this study identified leech species infesting yaks in Northeast India; only COI could delineate species, confirming genera Hirudinaria, Haemadipsa, and Whitmania and identifying Myxobdella annandalae, not previously recorded in the region.

Chatterjee N et al. · Mitochondrial DNA Part A

Genomics & Proteomics2016

Draft mitochondrial genomes of Hirudo medicinalis and Hirudo verbana (Annelida, Hirudinea)

This report presents two incomplete mitochondrial genome sequences from Hirudo medicinalis (14,729 bp) and Hirudo verbana (14,604 bp), each containing 13 protein-coding genes, 22 tRNAs and two rRNAs, and uses them to reconstruct phylogenetic relationships within Annelida.

Nikitina A et al. · Mitochondrial DNA. Part B, Resources

Salivary Pharmacology2025

SYNONYMIZATION OF PLACOBDELLA PICTA (VERRILL, 1872) (HIRUDINEA: GLOSSIPHONIIDAE) WITH DESCRIPTIONS OF TWO NEW SPECIES REVEALED BY MOLECULAR SPECIES DELIMITATION.

Species of Placobdella have been the frequent subject of revisionary and alpha-taxonomy in the past 2 decades.

Phillips AJ et al. · The Journal of parasitology

Related Resources

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.